Trial Profile
A Double-blind, Parallel Group, Randomised, Placebo Controlled, Multicenter, Bridging Phase III Study of Efficacy and Safety of KI1001 in the Improvement of Sleep Quality in >=55 Years Old Insomnia Patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2015
Price :
$35
*
At a glance
- Drugs Melatonin (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Kuhnil Pharmaceutical Company
- 23 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Apr 2012 Actual patient number is 170 according to ClinicalTrials.gov.
- 14 Oct 2011 New trial record